NVision, a healthcare technology startup, has raised US$55 million in a Series B funding round led by Abbott.
The company is expanding its work from quantum sensing technology into quantum computing solutions designed to support drug discovery and development.
NVision has developed a quantum-powered sensing platform called POLARIS. The technology improves MRI imaging by greatly increasing the signal from sugar-based imaging agents, helping doctors and researchers study body metabolism more clearly using standard MRI machines.
This allows researchers to understand how patients are responding to treatments within hours or days, instead of waiting weeks or months for traditional scans to show physical changes in the body.
“I see a future where quantum computers generate an explosion of drug hypotheses for diseases that are exceptionally difficult to treat today,” said Sella Brosh, CEO and Co-Founder of NVision. “As we expand our ambition into quantum computing, building on our remarkable new class of organic molecule-based qubits, that future comes closer. But without translational speed, we won’t fully realize those gains. POLARIS is built exactly to address this, enabling rapid in-vivo validation and closing the loop between design and reality.”
“NVision is fundamentally changing how we find, diagnose, and treat cancer by making the biology of disease visible in ways that weren’t possible before,” said Peter Barrett, General Partner, Playground Global. “That same molecular quantum capability now enables both the design and testing of new therapies – defining a new category in quantum health.”
NVision is a healthcare technology company founded by entrepreneurs and researchers from Israel and Germany in 2015. The company develops advanced medical imaging and quantum computing technologies for healthcare and drug discovery.
Read More- FusionAP raises $2 million in pre-seed round
